#United States #San Francisco #Mozart Therapeutics #MTX-201 #IBD Research

Mozart Therapeutics Unveils Promising New Preclinical Data on MTX-201

Mozart Therapeutics, a pioneer in developing modulators for CD8 Treg networks aimed at treating autoimmune diseases, unveiled compelling new preclinical data for its innovative product, MTX-201, at the 2025 Crohn's and Colitis Congress in San Francisco, California. This breakthrough event, occurring from February 6 to February 8, has garnered remarkable attention from experts in the field.

Understanding MTX-201

MTX-201 is a bispecific antibody designed to antagonize inhibitory killer immunoglobulin-like receptors (KIR) while fostering inducible T cell co-stimulation (ICOS) on CD8 T regulatory cells (Tregs). The data presented at the Congress demonstrated several critical aspects of how the antibody operates, particularly in its potential to effectively manage inflammatory bowel disease (IBD).

Key Findings Presented

During the event, the findings highlighted include:

• - Selective Binding and Activation: MTX-201 specifically binds to CD8 Tregs, activating them without triggering other immune cells that merely express one of the target proteins, such as other ICOS-expressing immune cells.
• - Survival and Disease Score Improvement: In a murine model for acute graft-versus-host disease (GvHD), there were notable extensions in survival rates and reductions in disease scores, indicating its efficiency in managing similar autoimmune responses.
• - Preservation of Immune Response: It does not inhibit immune reactions to common viral or microbial pathogens, which is crucial for maintaining overall immune health.
• - Enhanced Gut Cell Health: The antibody demonstrated a reduction in gut epithelial cell death and improved health in epithelial cells derived from tissues of Crohn's disease patients, suggesting a direct therapeutic impact on intestinal health.

Insights from Leadership

Dr. Courtney Crane, Senior Vice President of Translational Medicine at Mozart Therapeutics, expressed enthusiasm regarding these promising results derived from patient tissues. “We are excited to share our findings with leading experts at the Crohn's and Colitis Congress,” she stated. “This presentation signifies a major advancement in our second therapeutic program aimed at providing patients with potentially lasting relief from severe autoimmune diseases such as IBD.”

Presentation Details

The details of the presentation were distinctive:

• - Session Timing: February 7, 2025, from 5:00 PM to 6:30 PM Pacific Standard Time at the Exhibit and Poster Hall Reception in the Moscone Center.
• - Poster Information: The relevant poster #P129 focused on the preclinical trials related to the bispecific antibody targeting inhibitory KIR and ICOS aimed at treating IBD patients.

Following the session, the poster will be available on the Mozart Therapeutics website for further insights.

Potential Impact on Autoimmune Diseases

KIRs, which act as autoimmune checkpoints on CD8 Tregs, restrict their ability to eliminate pathogenic T cells effectively. In conditions marked by high inflammation like IBD, ICOS expression is heightened on activated CD8 Tregs, which is essential for their functionality.

MTX-201 acts to restore the function of these Tregs through inhibition of KIR while simultaneously promoting ICOS-mediated activation. This dual action is aimed at delivering solutions for chronic, highly inflammatory autoimmune disorders.

About Mozart Therapeutics

Headquartered in Seattle, WA, Mozart Therapeutics is dedicated to creating first-in-class therapies that modify disease pathways in autoimmune diseases. Their novel strategy emphasizes the restoration of immune system functions by specifically targeting the CD8 T regulatory network. For more information, visit Mozart Therapeutics and connect on LinkedIn.

Mozart is carving a distinctly promising path in the realm of autoimmune disease therapies, with MTX-201 spearheading their innovative approach and scientific discovery.